MPX Signs Definitive Agreement to Expand Its Footprint in Arizona

Medible review mpx signs definitive agreement to expand its footprint in arizona
Medible review mpx signs definitive agreement to expand its footprint in arizona

TORONTO, March 05, 2018 (GLOBE NEWSWIRE) — MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that the Company, through its wholly-owned U.S. subsidiary CGX Life Sciences Inc. (“CGX”), has entered into a definitive limited liability membership interest and asset purchase agreement, dated and effective March 1, 2018 to, acquire 100% of the membership units of ABACA, LLC (“ABACA”), Ambary, LLC, Tarmac Manufacturing, LLC (“Tarmac”) and Tower Management Holdings, LLC.  ABACA is a fully-integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act, A.R.S. Title 36, Section 28.1 (the “AMMA”) operating a dispensary under the trade name “The Holistic Center” in Phoenix, Arizona as well as certain real estate interests located at 21035 North Cave Creek Road, Phoenix, Arizona.

Closing of the transaction will proceed in due course according to the rules and policies of the Canadian Securities Exchange.

The Company will hold an investor call at 10:00 AM Eastern Standard Time on Thursday, March 8thto discuss this acquisition and MPX’s third quarter results. Conference call details will be announced in a press release to follow.

“This acquisition represents a solid addition to our industry and presence in Arizona, a State that offers MPX one of the best-regulated, yet industry-supportive markets in the country,” said W. Scott Boyes, MPX’s Chairman, President and CEO. “The entities being acquired have recorded trailing 12-month revenues of US$15 million and EBITDA of approximately US$3.5 million and its results will be immediately accretive to MPX earnings. Furthermore, the acquired companies are well-managed and will allow both parties to share best practises and benefit from the ability to share purchase economies. With the pending opening of our Apache Junction dispensary, the addition of the Holistic Center, will bring the number of dispensaries managed by MPX in the greater Phoenix market to four, will more than double our cultivation capacity and will materially complement our management team in the State. Adding to our critical mass of operations, this acquisition will add to MPX’s ability to benefit from purchasing economies, spread the administrative overhead costs over a larger revenue base and provide cash flows to support additional growth.”

“The Holistic Center began operations in October 2013 and has consistently been ranked as one of the top ten dispensaries in the State of Arizona,” said Bill Abbott, one of the founding partners.” All of our employees are extremely thrilled to be part of this new alignment with MPX and we look forward to adding value to the Company.”

Mr. Abbott will continue to oversee the operation of the acquired companies as Senior Vice President.

The Company is paying an aggregate of US$15,000,000 comprised of the following consideration:

  1. US$12,000,000 in cash;
  2. US$3,000,000 satisfied through the issuance of 5,704,479 common shares in the capital of MPX issued at a price of CAD$0.67. The Company determined the number of common shares issuable to the sellers by deeming the United States dollar / Canadian dollar currency conversion rate applicable for the issuance of Common Shares as 1.2740 Canadian dollars for each US$1.00 resulting in approximately CAD$3,822,000 for the US$3,000,000 portion of the purchase price to be satisfied by the issuance of common shares in the capital of MPX; and
  3. The issuance of 4,700,000 common share purchase warrants each exercisable into one (1) common share at an exercise price of CAD$0.67 for a period of five (5) years from the date of issuance.

In addition, CGX has a contingent liability of up to US$6,000,000 payable to the sellers solely out of the proceeds of the revenue generated from the contract between Tarmac and Timeless Select, LLC which is in the business of developing, producing and manufacturing essential oils and selling vaporizers and other marijuana products on behalf of ABACA.

About MPX Bioceutical Corporation

MPX, an Ontario corporation, through its wholly owned subsidiaries in the U.S., provides substantial management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to two medicinal cannabis enterprises in Arizona operating under the Health for Life (dispensaries) and the award-winning Melting Point Extracts (high-margin concentrates wholesale) brands. The successful Health for Life brand operates in the rapidly growing Phoenix Metropolitan Statistical Area.  With the acquisition of The Holistic Center, MPX adds a third operating medical cannabis enterprise to its footprint in Arizona.

GreenMart of Nevada NLV, LLC (“GreenMart”) is an award winning licensed cultivation, production and wholesale business, licensed for both the medical and “adult use” sectors in Las Vegas, Nevada, and is already selling wholesale into the Nevada medical cannabis market. GreenMart has also optioned suitable locations and intends to enter the higher-margin retail arena by applying for at least two dispensary licenses in the Las Vegas market which will operate under the “Health for Life” brand.

The Company owns assets in Massachusetts supporting cultivation, production and up to three dispensaries, and with the closing of this most recent transaction, MPX manages three full service dispensaries and one producer in Maryland.

MPX continues to expand its U.S. footprint, and has recently acquired management companies that provide operational and other services to three dispensaries and one production license in Maryland.  The Company also leases a property in Owen Sound, Ontario, for which an application to Health Canada has been made for a cannabis production and sales license. In addition, the Company will continue its efforts to develop its legacy nutraceuticals business.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX’s objectives and intentions.  Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX’s public documents filed on SEDAR at; and other matters discussed in this news release. Although MPX believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

On behalf of the Board of Directors

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO

For further information, please contact:

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO
[email protected]

Justin Canivet
T: +1-416-586-1942
[email protected]

Recommended Articles

Notify of

Inline Feedbacks
View all comments
Your questions and comments are welcome!x